Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 11

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 11
---
 blood cell infections caused by deer tick bites) in the United States   
 each year.10 Approximately 650 of these cases are hospitalizations, a smaller fraction of which represents immunosuppressed              
 individuals.11 Symptomatic babesiosis is usually treated with a minimum ten day course of atovaquone and azithromycin which              
 is extended to six weeks in the immunosuppressed, who may also experience relapses requiring multiple hospitalizations.12 This           
 is much longer than equivalent serious parasitic diseases such as malaria where the goal is a three-day regimen. In a recently published 
 case series Tafenoquine in combination with standard of care cured 80% of immunosuppressed patients with relapsing babesiosis and the    
 investigators stated in a press release that “Tafenoquine is going to make a huge difference,                                            
 I think, in people who are severely immunocompromised.” 13                                                                               |

| ● | Prevention of Tick-Borne Diseases. Post-exposure prophylaxis                                                                                  
 or early treatment with, respectively, a single dose or several week regimen of doxycycline following a tick-bite is a recognized indication  
 to prevent the complications of Lyme disease. There may be more than 400,000 such tick bites in the United States requiring medical treatment 
 each year. This estimate is based on the observation that approximately 50,000 tick bites are treated in U.S. hospital emergency rooms        
 each year; however, this calculation represents only about 12% of actual treated tick bites based on observations from comparable ex-U.S      
 health systems.14 Unlike Lyme disease, there is no characteristic rash associated with early infection and no reliable diagnostic             
 tests. Thus, an individual bitten by a tick cannot know whether they have also been infected with babesiosis. It is likely that a drug        
 proven to be effective for this indication for babesiosis would also be used in conjunction with Lyme prophylaxis.                            |

Treatment and Prevention of Fungal Infections We are evaluating Tafenoquine for potential utility in the following fungal diseases:

| ● | Treatment of Candida infections. According                                                                                             
 to the CDC, there are 50,000 reported cases of candidiasis (a type of fungal infection) each year in the United States and up to 1,900 
 clinical cases of C. auris, for which there are few available treatments.15 Since it has broad-spectrum activity                       
 against drug-resistant Candida spp in culture, Tafenoquine, has the potential to be